165 related articles for article (PubMed ID: 36733305)
1. Identification of single-dose, dual-echo based CBV threshold for fractional tumor burden mapping in recurrent glioblastoma.
Anil A; Stokes AM; Chao R; Hu LS; Alhilali L; Karis JP; Bell LC; Quarles CC
Front Oncol; 2023; 13():1046629. PubMed ID: 36733305
[TBL] [Abstract][Full Text] [Related]
2. Identification of a single-dose, low flip angle based CBV threshold for fractional tumor burden (FTB) mapping in recurrent glioblastoma.
Anil A; Stokes AM; Karis JP; Bell LC; Eschbacher J; Jennings K; Prah MA; Hu LS; Boxerman JL; Schmainda KM; Quarles CC
AJNR Am J Neuroradiol; 2024 May; ():. PubMed ID: 38782593
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of single bolus, dual-echo dynamic susceptibility contrast MRI protocols in brain tumor patients.
Stokes AM; Bergamino M; Alhilali L; Hu LS; Karis JP; Baxter LC; Bell LC; Quarles CC
J Cereb Blood Flow Metab; 2021 Dec; 41(12):3378-3390. PubMed ID: 34415211
[TBL] [Abstract][Full Text] [Related]
4. Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object.
Stokes AM; Semmineh NB; Nespodzany A; Bell LC; Quarles CC
Magn Reson Med; 2020 Jan; 83(1):109-123. PubMed ID: 31400035
[TBL] [Abstract][Full Text] [Related]
5. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
[TBL] [Abstract][Full Text] [Related]
6. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.
Hu LS; Kelm Z; Korfiatis P; Dueck AC; Elrod C; Ellingson BM; Kaufmann TJ; Eschbacher JM; Karis JP; Smith K; Nakaji P; Brinkman D; Pafundi D; Baxter LC; Erickson BJ
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2242-9. PubMed ID: 26359151
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional study to test equivalence of low- versus intermediate-flip angle dynamic susceptibility contrast MRI measures of relative cerebral blood volume in patients with high-grade gliomas at 1.5 Tesla field strength.
Shiroishi MS; Weinert D; Cen SY; Varghese B; Dondlinger T; Prah M; Mendoza J; Nazemi S; Ameli N; Amini N; Shohas S; Chen S; Bigjahan B; Zada G; Chen T; Neman-Ebrahim J; Chang EL; Chow FE; Fan Z; Yang W; Attenello FJ; Ye J; Kim PE; Patel VN; Lerner A; Acharya J; Hu LS; Quarles CC; Boxerman JL; Wu O; Schmainda KM
Front Oncol; 2023; 13():1156843. PubMed ID: 37799462
[TBL] [Abstract][Full Text] [Related]
8. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
9. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas.
Hu LS; Baxter LC; Pinnaduwage DS; Paine TL; Karis JP; Feuerstein BG; Schmainda KM; Dueck AC; Debbins J; Smith KA; Nakaji P; Eschbacher JM; Coons SW; Heiserman JE
AJNR Am J Neuroradiol; 2010 Jan; 31(1):40-8. PubMed ID: 19749223
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the Influence of Preload Dosing on Percent Signal Recovery (PSR) and Cerebral Blood Volume (CBV) Measurements in a Patient Population With High-Grade Glioma Using Dynamic Susceptibility Contrast MRI.
Bell LC; Hu LS; Stokes AM; McGee SC; Baxter LC; Quarles CC
Tomography; 2017 Jun; 3(2):89-95. PubMed ID: 28825039
[TBL] [Abstract][Full Text] [Related]
11. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
[TBL] [Abstract][Full Text] [Related]
12. Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
Xu Q; Liu Q; Ge H; Ge X; Wu J; Qu J; Xu K
Medicine (Baltimore); 2017 Dec; 96(50):e9332. PubMed ID: 29390403
[TBL] [Abstract][Full Text] [Related]
13. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
[TBL] [Abstract][Full Text] [Related]
14. Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.
Schmainda KM; Prah MA; Hu LS; Quarles CC; Semmineh N; Rand SD; Connelly JM; Anderies B; Zhou Y; Liu Y; Logan B; Stokes A; Baird G; Boxerman JL
AJNR Am J Neuroradiol; 2019 Apr; 40(4):626-633. PubMed ID: 30923088
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
Nierobisch N; Ludovichetti R; Kadali K; Fierstra J; Hüllner M; Michels L; Achangwa NR; Alcaide-Leon P; Weller M; Kulcsar Z; Hainc N
Eur J Radiol; 2023 Oct; 167():111076. PubMed ID: 37666072
[TBL] [Abstract][Full Text] [Related]
16. Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.
Schmainda KM; Prah MA; Rand SD; Liu Y; Logan B; Muzi M; Rane SD; Da X; Yen YF; Kalpathy-Cramer J; Chenevert TL; Hoff B; Ross B; Cao Y; Aryal MP; Erickson B; Korfiatis P; Dondlinger T; Bell L; Hu L; Kinahan PE; Quarles CC
AJNR Am J Neuroradiol; 2018 Jun; 39(6):1008-1016. PubMed ID: 29794239
[TBL] [Abstract][Full Text] [Related]
17. Analysis of postprocessing steps for residue function dependent dynamic susceptibility contrast (DSC)-MRI biomarkers and their clinical impact on glioma grading for both 1.5 and 3T.
Bell LC; Stokes AM; Quarles CC
J Magn Reson Imaging; 2020 Feb; 51(2):547-553. PubMed ID: 31206948
[TBL] [Abstract][Full Text] [Related]
18. Synthetic generation of DSC-MRI-derived relative CBV maps from DCE MRI of brain tumors.
Sanders JW; Chen HS; Johnson JM; Schomer DF; Jimenez JE; Ma J; Liu HL
Magn Reson Med; 2021 Jan; 85(1):469-479. PubMed ID: 32726488
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object.
Semmineh NB; Bell LC; Stokes AM; Hu LS; Boxerman JL; Quarles CC
AJNR Am J Neuroradiol; 2018 Nov; 39(11):1981-1988. PubMed ID: 30309842
[TBL] [Abstract][Full Text] [Related]
20. Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.
Muto M; Frauenfelder G; Senese R; Zeccolini F; Schena E; Giurazza F; Jäger HR
Radiol Med; 2018 Jul; 123(7):545-552. PubMed ID: 29508242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
